1. Europe In Vitro Diagnostics Market Outlook to 2018 - Clinical
Chemistry, Genetic Testing, Haematology, Histology and
Cytology, Immuno Chemistry, Infectious Immunology and
Microbiology Culture
Report Details:
Published:December 2012
No. of Pages: 445
Price: Single User License – US$3500
Europe In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry, Genetic Testing,
Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and
Microbiology Culture
Summary
GlobalData’s new report, “Europe In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry,
Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious
Immunology and Microbiology Culture” provides key market data on the Europe In Vitro
Diagnostics Market – Germany, France, Italy, Spain and United Kingdom. The report provides
value (USD million) data for all the market categories – Immuno Chemistry, Clinical Chemistry,
Haematology, Infectious Immunology, Microbiology Culture, Histology And Cytology and Genetic
Testing. The report also provides company shares and distribution shares data for each of the
aforementioned market categories. The report is supplemented with global corporate-level profiles
of the key market participants.
This report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
- Countries covered include Germany, France, Italy, Spain and United Kingdom.
- Market size and company share data for In Vitro Diagnostics market categories – Immuno
Chemistry, Clinical Chemistry, Haematology, Infectious Immunology, Microbiology Culture,
Histology And Cytology and Genetic Testing.
- Annualized market revenues (USD million) data for each of the market categories in each of the

2. country. Data from 2004 to 2011, forecast forward for 7 years to 2018.
- 2011 company shares and distribution shares data for each of the market categories and
countries.
- Global corporate-level profiles of key companies operating within the Europe In Vitro Diagnostics
market.
- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott
Laboratories, Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., bioMerieux S.A., Sysmex
Corporation, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, Alere Inc., DiaSorin
S.p.A, Phadia AB and Qiagen N.V.
Reasons to buy
- Develop business strategies by identifying the key market categories and segments poised for
strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the Europe In Vitro Diagnostics
competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to
register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product
distribution – Identify, understand and capitalize.
Get your copy of this report @
http://www.reportsnreports.com/reports/213233-europe-in-vitro-diagnostics-market-outlook-to-2018-clinical-
chemistry-genetic-testing-haematology-histology-and-cytology-immuno-chemistry-infectious-immunology-and-
microbiology-culture.html
Major points covered in Table of Contents of this report include
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 13
2 Introduction 15
2.1 What is This Report About? 15
3 In Vitro Diagnostics in Europe 16
3.1 In Vitro Diagnostics Cross Country Comparison 16
3.2 In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Constant, 2004-2018 17
3.3 In Vitro Diagnostics, Europe, Company share (2010-2011) 25
4 In Vitro Diagnostics In Germany 27
4.1 In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Constant, 2004-2018 27
4.2 In Vitro Diagnostics, Germany, Distribution Share (2010-2011) 33
4.3 In Vitro Diagnostics, Germany, Company Share (2010-2011) 37
5 In Vitro Diagnostics In France 53
5.1 In Vitro Diagnostics, France, Overall Revenue ($m), USD Constant, 2004-2018 53

3. 5.2 In Vitro Diagnostics, France, Distribution Share (2010-2011) 59
5.3 In Vitro Diagnostics, France, Company Share (2010-2011) 63
6 In Vitro Diagnostics In United Kingdom 79
6.1 In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, 2004-2018 79
6.2 In Vitro Diagnostics, United Kingdom, Distribution Share (2010-2011) 85
6.3 In Vitro Diagnostics, United Kingdom, Company Share (2010-2011) 89
7 In Vitro Diagnostics In Italy 105
7.1 In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Constant, 2004-2018 105
7.2 In Vitro Diagnostics, Italy, Distribution Share (2010-2011) 111
7.3 In Vitro Diagnostics, Italy, Company Share (2010-2011) 115
8 In Vitro Diagnostics In Spain 131
8.1 In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Constant, 2004-2018 131
8.2 In Vitro Diagnostics, Spain, Distribution Share (2010-2011) 137
8.3 In Vitro Diagnostics, Spain, Company Share (2010-2011) 141
9 Overview of Key Companies in Europe In Vitro Diagnostics Market 157
9.1 F. Hoffmann-La Roche Ltd. 157
9.2 Siemens Healthcare 158
9.3 Abbott Laboratories 159
9.4 Beckman Coulter, Inc. 160
9.5 Ortho-Clinical Diagnostics Inc. 161
9.6 bioMerieux S.A. 162
9.7 Sysmex Corporation 163
9.8 Bio-Rad Laboratories, Inc. 163
9.9 Becton, Dickinson and Company 164
9.10 Alere Inc. 164
9.11 DiaSorin S.p.A 165
9.12 Phadia AB 165
9.13 Qiagen N.V. 166
9.14 Diagnostica Stago, Inc. 166
9.15 Horiba, Ltd. 167
9.16 Gen-Probe Incorporated 167
9.17 PerkinElmer, Inc. 168
9.18 Mindray Medical International Limited 168
9.19 Thermo Fisher Scientific Inc. 169
9.20 ELITech Group 169
9.21 Grifols, S.A. 170
9.22 Danaher Corporation 170
9.23 Immucor, Inc. 171
9.24 Life Technologies Corporation 171
9.25 Hologic, Inc. 172
9.26 Innogenetics NV 172
9.27 Cellestis Limited 173

4. 10 In Vitro Diagnostics Market Pipeline Products 174
10.1 Clinical Chemisty Market Pipeline Products 174
10.2 Immuno Chemistry Market Pipeline Products 177
10.3 Haematology Market Pipeline Products 186
10.4 Infectious Immunology Market Pipeline Products 188
10.5 Microbiology Culture Market Pipeline Products 195
10.6 Histology And Cytology Market Pipeline Products 196
10.7 Genetic Testing Market Pipeline Products 197
11 Financial Deals Landscape 202
11.1 Acquisition 202
11.2 Partnerships 227
12 Recent Developments 357
12.1 Strategy And Business Planning 357
12.2 Research And Development 373
12.3 Government and Public Interest 380
12.4 Product News 392
13 Appendix 428
13.1 Definitions of Markets Covered in the Report 429
13.2 Research Methodology 430
13.3 Secondary Research 430
13.4 Primary Research 431
13.5 Models 431
13.6 Forecasts 432
13.7 Expert Panels 432
13.8 GlobalData Consulting 432
13.9 Currency Conversion 433
13.10 Contact Us 433
13.11 Disclaimer 433
1.1 List of Tables
Table 1: In Vitro Diagnostics, Cross Country Comparison, Revenue ($m),USD Constant, 2004-
2018 28
Table 2: In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Constant, 2004-2018 30
Table 3: In Vitro Diagnostics Market, Europe, Cross-Category Analysis, 2004-2018 32
Table 4: In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Constant, Historic, 2004-2011
34
Table 5: In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Constant, Forecast, 2011-2018
36
Table 6: In Vitro Diagnostics, Europe, Company share by Revenue ($m), USD Constant, 2010-
2011 38
Table 7: In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Constant, 2004-2018 40
Table 8: In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Constant, Historic, 2004-

5. 2011 42
Table 9: In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Constant, Forecast, 2011-
2018 44
Table 10: Clinical Chemistry, Germany, Distribution Share by Revenue ($m), USD Constant,
2010-2011 45
Table 11: Genetic Testing, Germany, Distribution Share by Revenue ($m), USD Constant, 2010-
2011 45
Table 12: Haematology, Germany, Distribution Share by Revenue ($m), USD Constant, 2010-
2011 46
Table 13: Histology And Cytology, Germany, Distribution Share by Revenue ($m), USD Constant,
2010-2011 46
Table 14: Immuno Chemistry, Germany, Distribution Share by Revenue ($m), USD Constant,
2010-2011 47
Table 15: Infectious Immunology, Germany, Distribution Share by Revenue ($m), USD Constant,
2010-2011 47
Table 16: Microbiology Culture, Germany, Distribution Share by Revenue ($m), USD Constant,
2010-2011 48
Table 17: In Vitro Diagnostics, Germany, Company Share by Revenue ($m), USD Constant, 2010-
2011 50
Table 18: Clinical Chemistry, Germany, Company Share by Revenue ($m), USD Constant, 2010-
2011 52
Table 19: Genetic Testing, Germany, Company Share by Revenue ($m), USD Constant, 2010-
2011 54
Table 20: Haematology, Germany, Company Share by Revenue ($m), USD Constant, 2010-2011
56
Table 21: Histology And Cytology, Germany, Company Share by Revenue ($m), USD Constant,
2010-2011 58
Table 22: Immuno Chemistry, Germany, Company Share by Revenue ($m), USD Constant, 2010-
2011 60
Table 23: Infectious Immunology, Germany, Company Share by Revenue ($m), USD Constant,
2010-2011 62
Table 24: Microbiology Culture, Germany, Company Share by Revenue ($m), USD Constant,
2010-2011 64
Table 25: In Vitro Diagnostics, France, Overall Revenue ($m), USD Constant, 2004-2018 66
Table 26: In Vitro Diagnostics, France, Overall Revenue ($m), USD Constant, Historic, 2004-2011
68
Table 27: In Vitro Diagnostics, France, Overall Revenue ($m), USD Constant, Forecast, 2011-
2018 70
Table 28: Clinical Chemistry, France, Distribution Share by Revenue ($m), USD Constant, 2010-
2011 71
Table 29: Genetic Testing, France, Distribution Share by Revenue ($m), USD Constant, 2010-
2011 71

6. Table 30: Haematology, France, Distribution Share by Revenue ($m), USD Constant, 2010-2011
72
Table 31: Histology And Cytology, France, Distribution Share by Revenue ($m), USD Constant,
2010-2011 72
Table 32: Immuno Chemistry, France, Distribution Share by Revenue ($m), USD Constant, 2010-
2011 73
Table 33: Infectious Immunology, France, Distribution Share by Revenue ($m), USD Constant,
2010-2011 73
Table 34: Microbiology Culture, France, Distribution Share by Revenue ($m), USD Constant,
2010-2011 74
Table 35: In Vitro Diagnostics, France, Company Share by Revenue ($m), USD Constant, 2010-
2011 76
Table 36: Clinical Chemistry, France, Company Share by Revenue ($m), USD Constant, 2010-
2011 78
Table 37: Genetic Testing, France, Company Share by Revenue ($m), USD Constant, 2010-2011
80
Table 38: Haematology, France, Company Share by Revenue ($m), USD Constant, 2010-2011 82
Table 39: Histology And Cytology, France, Company Share by Revenue ($m), USD Constant,
2010-2011 84
Table 40: Immuno Chemistry, France, Company Share by Revenue ($m), USD Constant, 2010-
2011 86
Table 41: Infectious Immunology, France, Company Share by Revenue ($m), USD Constant,
2010-2011 88
Table 42: Microbiology Culture, France, Company Share by Revenue ($m), USD Constant, 2010-
2011 90
Table 43: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, 2004-2018
92
Table 44: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, Historic,
2004-2011 94
Table 45: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, Forecast,
2011-2018 96
Table 46: Clinical Chemistry, United Kingdom, Distribution Share by Revenue ($m), USD
Constant, 2010-2011 97
Table 47: Genetic Testing, United Kingdom, Distribution Share by Revenue ($m), USD Constant,
2010-2011 97
Table 48: Haematology, United Kingdom, Distribution Share by Revenue ($m), USD Constant,
2010-2011 98
Table 49: Histology And Cytology, United Kingdom, Distribution Share by Revenue ($m), USD
Constant, 2010-2011 98
Table 50: Immuno Chemistry, United Kingdom, Distribution Share by Revenue ($m), USD
Constant, 2010-2011 99
Table 51: Infectious Immunology, United Kingdom, Distribution Share by Revenue ($m), USD

7. Constant, 2010-2011 99
Table 52: Microbiology Culture, United Kingdom, Distribution Share by Revenue ($m), USD
Constant, 2010-2011 100
Table 53: In Vitro Diagnostics, United Kingdom, Company Share by Revenue ($m), USD
Constant, 2010-2011 102
Table 54: Clinical Chemistry, United Kingdom, Company Share by Revenue ($m), USD Constant,
2010-2011 104
Table 55: Genetic Testing, United Kingdom, Company Share by Revenue ($m), USD Constant,
2010-2011 106
Table 56: Haematology, United Kingdom, Company Share by Revenue ($m), USD Constant,
2010-2011 108
Table 57: Histology And Cytology, United Kingdom, Company Share by Revenue ($m), USD
Constant, 2010-2011 110
Table 58: Immuno Chemistry, United Kingdom, Company Share by Revenue ($m), USD Constant,
2010-2011 112
Table 59: Infectious Immunology, United Kingdom, Company Share by Revenue ($m), USD
Constant, 2010-2011 114
Table 60: Microbiology Culture, United Kingdom, Company Share by Revenue ($m), USD
Constant, 2010-2011 116
Table 61: In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Constant, 2004-2018 118
Table 62: In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Constant, Historic, 2004-2011
120
Table 63: In Vitro Diagnostics, Italy, Overall Revenue ($m), USD Constant, Forecast, 2011-2018
122
Table 64: Clinical Chemistry, Italy, Distribution Share by Revenue ($m), USD Constant, 2010-2011
123
Table 65: Genetic Testing, Italy, Distribution Share by Revenue ($m), USD Constant, 2010-2011
123
Table 66: Haematology, Italy, Distribution Share by Revenue ($m), USD Constant, 2010-2011 124
Table 67: Histology And Cytology, Italy, Distribution Share by Revenue ($m), USD Constant,
2010-2011 124
Table 68: Immuno Chemistry, Italy, Distribution Share by Revenue ($m), USD Constant, 2010-
2011 125
Table 69: Infectious Immunology, Italy, Distribution Share by Revenue ($m), USD Constant, 2010-
2011 125
Table 70: Microbiology Culture, Italy, Distribution Share by Revenue ($m), USD Constant, 2010-
2011 126
Table 71: In Vitro Diagnostics, Italy, Company Share by Revenue ($m), USD Constant, 2010-2011
128
Table 72: Clinical Chemistry, Italy, Company Share by Revenue ($m), USD Constant, 2010-2011
130
Table 73: Genetic Testing, Italy, Company Share by Revenue ($m), USD Constant, 2010-2011

8. 132
Table 74: Haematology, Italy, Company Share by Revenue ($m), USD Constant, 2010-2011 134
Table 75: Histology And Cytology, Italy, Company Share by Revenue ($m), USD Constant, 2010-
2011 136
Table 76: Immuno Chemistry, Italy, Company Share by Revenue ($m), USD Constant, 2010-2011
138
Table 77: Infectious Immunology, Italy, Company Share by Revenue ($m), USD Constant, 2010-
2011 140
Table 78: Microbiology Culture, Italy, Company Share by Revenue ($m), USD Constant, 2010-
2011 142
Table 79: In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Constant, 2004-2018 144
Table 80: In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Constant, Historic, 2004-2011
146
Table 81: In Vitro Diagnostics, Spain, Overall Revenue ($m), USD Constant, Forecast, 2011-2018
148
Table 82: Clinical Chemistry, Spain, Distribution Share by Revenue ($m), USD Constant, 2010-
2011 149
Table 83: Genetic Testing, Spain, Distribution Share by Revenue ($m), USD Constant, 2010-2011
149
Table 84: Haematology, Spain, Distribution Share by Revenue ($m), USD Constant, 2010-2011
150
Table 85: Histology And Cytology, Spain, Distribution Share by Revenue ($m), USD Constant,
2010-2011 150
Table 86: Immuno Chemistry, Spain, Distribution Share by Revenue ($m), USD Constant, 2010-
2011 151
Table 87: Infectious Immunology, Spain, Distribution Share by Revenue ($m), USD Constant,
2010-2011 151
Table 88: Microbiology Culture, Spain, Distribution Share by Revenue ($m), USD Constant, 2010-
2011 152
Table 89: In Vitro Diagnostics, Spain, Company Share by Revenue ($m), USD Constant, 2010-
2011 154
Table 90: Clinical Chemistry, Spain, Company Share by Revenue ($m), USD Constant, 2010-2011
156
Table 91: Genetic Testing, Spain, Company Share by Revenue ($m), USD Constant, 2010-2011
158
Table 92: Haematology, Spain, Company Share by Revenue ($m), USD Constant, 2010-2011 160
Table 93: Histology And Cytology, Spain, Company Share by Revenue ($m), USD Constant,
2010-2011 162
Table 94: Immuno Chemistry, Spain, Company Share by Revenue ($m), USD Constant, 2010-
2011 164
Table 95: Infectious Immunology, Spain, Company Share by Revenue ($m), USD Constant, 2010-
2011 166

9. Table 96: Microbiology Culture, Spain, Company Share by Revenue ($m), USD Constant, 2010-
2011 168
Table 97: Clinical Chemisty Market Pipeline Products 186
Table 98: Immuno Chemistry Market Pipeline Products 189
Table 99: Haematology Market Pipeline Products 198
Table 100: Infectious Immunology Market Pipeline Products 200
Table 101: Microbiology Culture Market Pipeline Products 207
Table 102: Histology And Cytology Market Pipeline Products 208
Table 103: Genetic Testing Market Pipeline Products 209
Table 104: Amgen To Acquire Decode Genetics, Human Genetics Company, For $415 Million 214
Table 105: VWR International Acquires Labonord, Histology Reagents Supplier 216
Table 106: VWR International Acquires Switch, Cytology And Histology Reagents Manufacturer
217
Table 107: Trivitron Healthcare Acquires Ani Labsystems For $20.3 Million 218
Table 108: Exonhit To Acquire InGen BioSciences From Innoven Partenaires And Amundi Private
Equity For $23 Million 219
Table 109: Erba Lachema Acquires Maxmat, Maker Of Automated Analyzers And Reagents 221
Table 110: Illumina Acquires BlueGnome, Provider Of Cytogenetics And In Vitro Fertilization
Screening Solutions 222
Table 111: Sias To Acquire Xiril, Lab Equipment Maker 223
Table 112: Becton, Dickinson Acquires Sirigen, Developer Of Polymer Dyes 224
Table 113: Abingdon Health Acquires 80% Stake In Forsite Diagnostics 226
Table 114: Agilent Technologies Completes Acquisition Of Dako From EQT For $2.2 Billion 227
Table 115: Ametek Completes Acquisition Of Dunkermotoren From Triton Advisers For $330
Million 229
Table 116: Abingdon Health To Acquire 50.1% Stake In Molecular Vision From Imperial
Innovations Group 230
Table 117: Trinity Biotech To Acquire Fiomi Diagnostics From Alfven & Didrikson For $13.1 Million
231
Table 118: Unisense FertiliTech Plans Sale Of The Company 232
Table 119: Echosens Acquires BioLiveScale, Provider Of Biomarkers For Liver Diseases 233
Table 120: Harvard Bioscience Acquires AHN Biotechnologie, Maker Of Plastic Consumable Lab
Products, For $2.6 Million 234
Table 121: B. Braun Melsungen Acquires 20% Stake In CeGaT 235
Table 122: Addtech Life Science Acquires Reagent And Instrument Firm, BioNordika Group 236
Table 123: Quintiles Acquires Minority Stake In Oxford Cancer Biomarkers For $5 Million 237
Table 124: Eppendorf Acquires Dasgip Group, Developer Of Bioreactor Systems 238
Table 125: Galena Biopharma Enters Into Co-Development Agreement With Leica Biosystems
239
Table 126: Cisbio Bioassays Enters Into Distribution Agreement With BellBrook Labs For
Transcreener Epigen Methyltransferase Assay 240
Table 127: Evotec Enters Into Co-Development Agreement With Probiodrug For Glutaminyl

10. Cyclase 242
Table 128: Pressure BioSciences Enters Into Co-Marketing Agreement With Constant Systems
For High Pressure Technologies 243
Table 129: BioCat Enters Into Distribution Agreement With Alpco Diagnostics For ELISA Kits 244
Table 130: bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology
245
Table 131: Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery
246
Table 132: Scienion Enters Into Co-Development Agreement With Genomica 247
Table 133: Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments For
Archimedes Particle Metrology System 248
Table 134: Qiagen Enters Into Agreement With Bayer HealthCare To Develop Diagnostics Test In
Oncology 249
Table 135: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 250
Table 136: Phthisis Diagnostics Enters Into Distribution Agreement With Elitech Group 251
Table 137: BioDot Enters Into Co-Marketing Agreement With JOT Automation 252
Table 138: Merck Serono Enters Into Co-Development Agreement With Auxogyn For Early
Embryo Viability Assessment Test 253
Table 139: AbD Serotec Enters Into Licensing Agreement With DiaSorin For HuCAL Antibodies
254
Table 140: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology
Assays 255
Table 141: Trillium Diagnostics Enters Into Licensing Agreement With Leukocare For Sepsis Dx
256
Table 142: CellaVision Enters Into Distribution Agreement With Siemens Healthcare For Digital
Microscopy Hematology Solutions 257
Table 143: Med BioGene Amends Licensing Agreement With Precision Therapeutics For
LungExpress Dx Test 258
Table 144: Thermo Fisher Scientific Extends Co-Development Agreement With bioMerieux For
Procalcitonin Testing 259
Table 145: Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon
Biotechnology 261
Table 146: Curetis Enters Into Co-Development Agreement With Heraeus Medical For Unyvero
262
Table 147: Life Technologies Enters Into Co-Marketing Agreement With Pathogenica 263
Table 148: Genalyte Partners Scienion To Provide Sciflexarrayer Dispensers For Maverick
Detection Platform 264
Table 149: CML HealthCare Enters Into Agreement With MaRS Innovation 265
Table 150: Akrivis Technologies Enters Into Co-Development Agreement With United States
Biological 266
Table 151: Agilent Technologies Enters Into Co-Marketing Agreement With Molecular Discovery
267

11. Table 152: Castle Biosciences Enters Into Licensing Agreement With Brigham and Women''s
Hospital For Mesothelioma Test 268
Table 153: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein
Array Products 269
Table 154: GeneCentric Diagnostics Enters Into Licensing Agreement With University of North
Carolina 270
Table 155: Dolomite Centre Enters Into Licensing Agreement With Japan Science and Technology
Agency For Microdroplet Generation Technology 271
Table 156: InGen BioSciences Enters Into Distribution Agreement With Quidel 272
Table 157: InGen BioSciences Enters Into Distribution Agreement With Diagnostic Hybrids 273
Table 158: University of Limerick Enters Into Co-Development Agreement With GenCell 274
Table 159: NewBridge Pharma Enters Into Licensing Agreement With Genomic Health For
Oncotype DX Tests 275
Table 160: Curetis Enters Into Licensing Agreement With Cempra For Unyvero 277
Table 161: Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium
TB Test 278
Table 162: Waters Enters Into Co-Development Agreement With Nonlinear Dynamics 279
Table 163: EKF Diagnostics Enters Into Licensing Agreement With Joslin Diabetes Center 280
Table 164: SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For
PhenoFluor 281
Table 165: Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 282
Table 166: BioView Enters Into Co-Development Agreement With ScreenCell For Circulating
Tumor Cell Analysis Technology 283
Table 167: MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test
284
Table 168: PlexPress Enters Into Technology Integration Agreement With Phalanx Biotech 285
Table 169: Lab21 Enters Into Co-Development Agreement With Pharma Company 286
Table 170: Kreatech Diagnostics Enters Into Co-Development Agreement With Oridis Biomarkers
For DNA-FISH Assays 287
Table 171: Courtagen Life Sciences Enters Into Licensing Agreement With Scienion For
sciFlexArrayer Technology 288
Table 172: NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For
AdenoPlus 289
Table 173: Leica Microsystems Enters Into Integration Agreement With Indica Labs 291
Table 174: ImaBiotech Enters Into Agreement With Genfit 292
Table 175: Epigenomics Enters Into Licensing Agreement With Companion Dx Reference Lab For
Septin9 Biomaker 293
Table 176: Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 294
Table 177: Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4
POC Test 295
Table 178: KineMed Enters Into Co-Development Agreement With GlaxoSmithKline 296
Table 179: RayBiotech Enters Into Agreement With Oslo University Hospital And University of

12. Oslo 297
Table 180: One Lambda Enters Into Co-Marketing Agreement With CellTrend 298
Table 181: InGen BioSciences Enters Into Co-Marketing Agreement With Cylex For ImmuKnow
Assays 299
Table 182: BioGenes Enters Into Co-Development Agreement With Boehringer Ingelheim 300
Table 183: GE Healthcare Enters Into Co-Development Agreement With Commonwealth Scientific
and Industrial Research 301
Table 184: Foundation Medicine Extends Co-Development Agreement With Novartis 302
Table 185: Sebia Enters Into Co-Development Agreement With Institut National de la Sante And
Inserm Transfert 303
Table 186: Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics
For ALK Cancer Biomarker 304
Table 187: Ventana Medical Enters Into Licensing Agreement With German Cancer Research
Center And University Hospital Heidelberg For BRAF V600E 305
Table 188: Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 307
Table 189: Radisens Diagnostics Enters Into Co-Development Agreement With Beckman Coulter
For HDR Detection Technology 308
Table 190: Biohit Enters Into Distribution Agreement With Euro-Diagnostica For GastroPanel 309
Table 191: Biocartis Enters Into Co-Development Agreement With Wellcome Trust Sanger
Institute And Philips Research Europe For Oncology Diagnostics 310
Table 192: Seegene Enters Into Co-Development Agreement With DuPont Nutrition & Health To
Develop Multiplexed Assays For Food Safety Testing 311
Table 193: Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG
Marker 312
Table 194: Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor
Cell Technology 313
Table 195: Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 314
Table 196: Dako Announces Licensing Agreement With Van Andel Research Institute For Cancer
Diagnostic Tool 315
Table 197: Isogen Life Science Enters Into Co-Marketing Agreement With Axela For Biomarker
Analysis Platforms 316
Table 198: Multiplicom Enters Into Co-Development Agremment With Institute for
Cardiometabolism And Institut Du Cerveau 317
Table 199: Opko Health Enters Into Licensing Agreement With International Health Technology
For Prostate Cancer Biomarker Panel 318
Table 200: ZyGem Enters Into Co-Marketing Agreement With Tataa Biocenter 319
Table 201: Dolomite Centre Enters Into Co-Development Agreement With LioniX 320
Table 202: Applied Microarrays Enters Into Co-Development Agreement With Sensovation For
FlexiPlex Array System 321
Table 203: Nanosphere Enters Into Co-Marketing Agreement With Thermo Fisher For Verigene
Products 322
Table 204: Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For

13. LongRange PCR Kit 323
Table 205: Denator Enters Into Co-Development Agreement With Erasmus And Amsterdam
Medical For Cancer Biomarker Platform 324
Table 206: Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 325
Table 207: Novo Nordisk Enters Into Co-Development Agreement With Oxford University 326
Table 208: Pressure BioSciences Enters Into Licensing Agreement With Target Discovery For
Pressure Cycling Technology 327
Table 209: LipoScience Enters Into Licensing Agreement With Cleveland Clinic 328
Table 210: GE Healthcare Enters Into Co-Development Agreement With NXT2B For Compact
Cyclotron And PET Tracer System 329
Table 211: Sysmex Extends Distribution Agreement With Roche 330
Table 212: Rubicon Genomics Enters Into Technology Integration Agreement With Kreatech
Diagnostics 331
Table 213: NexDx Enters Into Licensing Agreement With University of California For Epigenetic
Biomarkers 332
Table 214: Elchrom Scientific Enters Into Technology Integration Agreement With Biotium 333
Table 215: RayBiotech Enters Into Co-Marketing Agreement With Innopsys 334
Table 216: LAB21 Enters Into Co-Development Agreement With IVD Company For Aspergillus
Molecular Assay 335
Table 217: Randox Labs Enters Into Licensing Agreement With Proteome Sciences For Stroke
Biomarker 336
Table 218: Bernhard Nocht Institute Enters Into Co-Development Agreement With altona
DIAGNOSTICS 337
Table 219: Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 338
Table 220: Accuray Enters Into Co-Development Agreement With University of Heidelberg 339
Table 221: A*STAR Enters Into Co-Development Agreement With QuantuMDx Group 340
Table 222: DiaGenic Enters Into Co-Development Agreement With GE Healthcare 341
Table 223: DNA Electronics Enters Into Licensing Agreement With Gene Onyx For Genalysis
Technology 342
Table 224: Protagen Enters Into Co-Development Agreement With University of Tuebingen 343
Table 225: Epistem Holdings Enters Into Co-Development Agreement With GlaxoSmithKline 344
Table 226: Saladax Biomedical Enters Into Co-Marketing Agreement With INyDIA Laboratorios
Biomedical Diagnostics For My5-FU 345
Table 227: Hamilton Thorne Expands Co-Marketing Agreement With Leica Microsystems 346
Table 228: ANGLE Enters Into Co-Development Agreement With Paterson Institute for Cancer
Research 347
Table 229: Yissum Research Development Company Enters Into Licensing Agreement With
BioConnections For Commercialization Of Kits 348
Table 230: Radisens Enters Into Licensing Agreement With Tecan 349
Table 231: Apceth Enters Into Co-Development Agreement With Indivumed For Biomarker
Platform 350
Table 232: Oxford Gene Technology Enters Into Licensing Agreement With Oslo University

14. Hospital And University of Oslo 351
Table 233: Roche Enters Into Licensing Agreement With Life Technologies For PCR Technology
352
Table 234: Dako Enters Into Co-Development Agreement With Amgen 353
Table 235: VolitionRx And Abcodia Partner To Advance Discovery Of Blood Based Biomarkers
For Cancer 354
Table 236: Integromics Enters Into Co-Development Agreement With Galician Foundation Of
Genomic Medicine 355
Table 237: Horizon Diagnostics Enters Into Licensing Agreement With UK NEQAS 356
Table 238: Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCT
Assay For Sepsis 357
Table 239: Crossbeta Biosciences, Good Biomarker Sciences And U-Protein Express Partner To
Develop Alzheimer’s Disease Biomarker 358
Table 240: OPKO Health Enters Into Licensing Agreement With Arctic Partners For Biomakers
359
Table 241: Roche Enters Into Co-Development Agreement With Technoclone 360
Table 242: Dako Enters Into Co-Development Agreement With Amgen 361
Table 243: Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic
Biomarkers And Potential Diagnostics 362
Table 244: QIAGEN Enters Into Co-Development Agreement With Max Planck Institute 363
Table 245: Amorfix Life Sciences Enters Into Licensing Agreement With JSW-Lifesciences 364
Table 246: Boulder Diagnostics Enters Into Licensing Agreement With RUNMC 365
Table 247: HansaBioMed, Poliedra Sanita, Siena Biotech And Biofund Partner To Form
Exosomics Siena 366
Table 248: Global BioDiagnostics Extends Co-Development Agreement With Foundation for
Innovative New Diagnostics 367
Table 249: Sony DADC Enters Into Co-Development Agreement With Axela 368
1.2 List of Figures
Figure 1: In Vitro Diagnostics, Cross Country Comparison, Revenue ($m), USD Constant, 2004-
2018 28
Figure 2: In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Constant, 2004-2018 29
Figure 3: In Vitro Diagnostics Market, Europe, Cross-Category Analysis, 2004-2018 31
Figure 4: In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Constant, Historic, 2004-2011
33
Figure 5: In Vitro Diagnostics, Europe, Overall Revenue ($m), USD Constant, Forecast, 2011-
2018 35
Figure 6: In Vitro Diagnostics, Europe, Company share (%), 2011 37
Figure 7: In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Constant, 2004-2018 39
Figure 8: In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Constant, Historic, 2004-
2011 41
Figure 9: In Vitro Diagnostics, Germany, Overall Revenue ($m), USD Constant, Forecast, 2011-

15. 2018 43
Figure 10: In Vitro Diagnostics, Germany, Company Share (%), 2011 49
Figure 11: Clinical Chemistry, Germany, Company Share (%), 2011 51
Figure 12: Genetic Testing, Germany, Company Share (%), 2011 53
Figure 13: Haematology, Germany, Company Share (%), 2011 55
Figure 14: Histology And Cytology, Germany, Company Share (%), 2011 57
Figure 15: Immuno Chemistry, Germany, Company Share (%), 2011 59
Figure 16: Infectious Immunology, Germany, Company Share (%), 2011 61
Figure 17: Microbiology Culture, Germany, Company Share (%), 2011 63
Figure 18: In Vitro Diagnostics, France, Overall Revenue ($m), USD Constant, 2004-2018 65
Figure 19: In Vitro Diagnostics, France, Overall Revenue ($m), USD Constant, Historic, 2004-2011
67
Figure 20: In Vitro Diagnostics, France, Overall Revenue ($m), USD Constant, Forecast, 2011-
2018 69
Figure 21: In Vitro Diagnostics, France, Company Share (%), 2011 75
Figure 22: Clinical Chemistry, France, Company Share (%), 2011 77
Figure 23: Genetic Testing, France, Company Share (%), 2011 79
Figure 24: Haematology, France, Company Share (%), 2011 81
Figure 25: Histology And Cytology, France, Company Share (%), 2011 83
Figure 26: Immuno Chemistry, France, Company Share (%), 2011 85
Figure 27: Infectious Immunology, France, Company Share (%), 2011 87
Figure 28: Microbiology Culture, France, Company Share (%), 2011 89
Figure 29: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, 2004-
2018 91
Figure 30: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, Historic,
2004-2011 93
Figure 31: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, Forecast,
2011-2018 95
Figure 32: In Vitro Diagnostics, United Kingdom, Company Share (%), 2011 101
Figure 33: Clinical Chemistry, United Kingdom, Company Share (%), 2011 103
Figure 34: Genetic Testing, United Kingdom, Company Share (%), 2011 105
Figure 35: Haematology, U
Contact: sales@reportsandreports.com for more information.